NYSE:HIMSHealthcare
Hims And Hers Faces GLP-1 Setback While Expanding Into Longevity Care
Hims & Hers Health (NYSE:HIMS) has halted its newly launched compounded GLP-1 weight loss pill only days after introducing it.
The move follows a lawsuit from Novo Nordisk over compounded weight loss drugs and increased FDA scrutiny of these products.
The company is shifting its focus toward longevity and diagnostics, including hormone therapy and early cancer detection services.
Hims & Hers Health, known for its direct to consumer telehealth model across categories like mental health, hair...